Archive for March, 2010

PCMA: Federal Enrollees Don’t Want Congress to Reduce Pharmacy Choices, Impose Price Controls in FEHBP

Wednesday, March 24th, 2010

Polling Shows 74% of FEHBP Enrollees Oppose Key Components of the Lynch Bill

(Washington, DC)— Pharmaceutical Care Management Association (PCMA) President and CEO Mark Merritt issued the following statement on today’s Federal Workforce, Postal Service, and District of Columbia Subcommittee on House Oversight and Government Reform Committee markup of the FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act (H.R. 4489).  Currently, the Federal Employees Health Benefits Program (FEHBP) uses the same approach to pharmacy benefits as Fortune 500 companies, Medicare Part D, and other benefits programs which rely upon consumer choice and competition rather than price controls to hold down costs and maintain flexible benefits. In the bill, Congress would force the Office of Personnel Management (OPM), which oversees FEHBP, to change the pharmacy benefits it offers:

“Seventy-four percent of those enrolled in FEHBP oppose a new effort by Congress to reduce pharmacy choices, arbitrarily set prices, and limit the number of pharmacy organizations which can participate in the program.

“FEHBP enrollees feel that OPM does a great job managing the program and think Congress is more likely to hurt than help the program by forcing OPM to change FEHBP’s pharmacy benefits.

“This was highlighted in a recent bipartisan focus group of FEHBP enrollees in Fairfax County, Virginia, who were deeply skeptical not only of the Lynch bill, but of the broader idea of Congress micromanaging how OPM administers the program.”

Posted in Cost Savings, Generics, Mail-Service Pharmacy Option, Medicare Prescription Drug Benefit, Pharmacy, Pharmacy Management Tools, Press Release | No Comments »

New Survey: Three in Four Enrollees Oppose Legislation to Change FEHBP

Wednesday, March 10th, 2010

Poll Finds Overwhelming Satisfaction with FEHBP Pharmacy Benefit;

Most Think Bill Would Hurt, Not Help 

(Washington, DC)— Seventy-four percent of those enrolled in the Federal Health Benefits Program (FEHBP) oppose a new effort by Congress to change the program’s prescription drug benefits, according to a new poll released by the Pharmaceutical Care Management Association (PCMA).  

The survey of 305 civilian federal employees in the Washington, DC metro area was conducted in response to the FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act (H.R. 4489) sponsored by Representatives Stephen Lynch (D-MA), Gerald Connolly (D-VA), Elijah Cummings (D-MD), and Lloyd Doggett (D-TX).  The bill would give Congress the power to set prices, limit the pharmacy organizations that can participate, and force the Office of Personnel Management (OPM), which administers FEHBP, to make other changes as well.

Currently, FEHBP uses the same approach to pharmacy benefits as Fortune 500 companies, Medicare Part D and other benefits programs which rely upon consumer choice and competition rather than price controls to hold down costs and maintain flexible benefits.  Eighty-three percent of FEHBP’s enrollees are satisfied with their prescription drug coverage, according to the survey.

“These new data clearly show that politicians supporting legislation to change FEHBP’s pharmacy benefit could be walking into a political minefield.  By lopsided margins, federal workers like their prescription drug benefits, like the way OPM administers FEHBP, and think Congress could make things worse, not better, by trying to micromanage it,” said PCMA President and CEO Mark Merritt. 

Key findings from the Ayres, McHenry & Associates survey include:

Posted in Cost Savings, Generics, Medicare Prescription Drug Benefit, Pharmacy Management Tools, Press Release, State and Legal Issues | No Comments »

Survey of Federal Employees Regarding FEHBP Drug Benefit

Wednesday, March 10th, 2010

Survey of Federal Employees Regarding FEHBP Drug Benefit

Posted in All Sections, Press Release, Research | No Comments »

PCMA: New GAO Report Highlights the Need for Meaningful Biogenerics Reform

Monday, March 1st, 2010

Accelerate Competition to Lower Costs, Increase Access

(Washington, DC)— The Pharmaceutical Care Management Association (PCMA) released the following statement today on a new Government Accountability Office (GAO) report examining specialty-tier prescription drugs in Medicare Part D:

“The high prices of biotech drugs in the new GAO report underscore the importance of creating much-needed competition to lower costs and increase access for these life-saving products.  Many of the high-cost biotech medicines examined by GAO do not face generic competition, straining public and private payers’ ability to provide affordable drug benefits for these necessary and often life-changing products.  Generic competition lowers costs because it gives patients the power to choose and gives manufacturers an incentive to reduce prices. 

“Meaningful biogenerics legislation should be the first stop for policymakers tasked with financing health reform. PCMA and a broad coalition of consumers, employers, labor unions, and others support bipartisan legislation that would create a regulatory pathway for the Food and Drug Administration to approve generic versions of biologic products.”

 

###

Posted in Cost Savings, Generics, Medicare Prescription Drug Benefit, Pharmacy Management Tools, Press Release, Specialty Pharmacy, State and Legal Issues | No Comments »